IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Based on our 6-factor quantitative model, GSK plc (GSK) is the stronger stock with a composite score of 74.3/100 and a Buy rating, compared to Neumora Therapeutics, Inc. (NMRA) at 39.8/100 (Avoid). GSK ranks #18 in our universe versus #3560 for NMRA, giving it an edge of 34.5 points across quality, value, momentum, investment, stability, and short interest factors.
For the Quality factor — which measures profitability and business quality through metrics like ROE, gross margins, and capital efficiency — GSK leads at 84/100, while NMRA trails at 18/100 (GSK: 84/100, NMRA: 18/100). The 66-point gap indicates a meaningful difference in quality characteristics between these stocks.
For the Value factor — which evaluates whether a stock is cheap or expensive relative to its earnings, book value, and cash flows — GSK leads at 90/100, while NMRA trails at 13/100 (GSK: 90/100, NMRA: 13/100). The 77-point gap indicates a meaningful difference in value characteristics between these stocks.
On the Momentum factor, which captures price trends and institutional sentiment over the trailing 3-12 months, these stocks are closely matched (GSK: 70/100, NMRA: 67/100). The narrow 4-point spread suggests similar momentum profiles, so this factor alone is unlikely to be a decisive differentiator.
For the Investment factor — which assesses capital allocation quality including reinvestment rates and asset growth — GSK leads at 67/100, while NMRA trails at 25/100 (GSK: 67/100, NMRA: 25/100). The 42-point gap indicates a meaningful difference in investment characteristics between these stocks.
For the Stability factor — which measures financial health through leverage ratios and price volatility — GSK leads at 89/100, while NMRA trails at 27/100 (GSK: 89/100, NMRA: 27/100). The 62-point gap indicates a meaningful difference in stability characteristics between these stocks.
For the Short Interest factor — which tracks institutional bearish positioning and potential risk from elevated short selling — GSK leads at 53/100, while NMRA trails at 43/100 (GSK: 53/100, NMRA: 43/100). The 10-point gap indicates a meaningful difference in short interest characteristics between these stocks.
Based on our 6-factor model, GSK plc (GSK) is utilizing a stronger overall profile than NMRA, with a Composite Score of 74 vs 40. This represents a significant advantage. GSK dominates specifically in Value (+77 points) and Quality, making it the clear quantitative winner.
| Overall Rating | ||
| Composite Score | 74 | 40 |
| Rank | #18 | #3,560 |
| Stars | 4 / 5 | 1 / 5 |
| Action | Buy | Avoid |
| Factor Scores | ||
| Quality | 84 | 18 |
| Value | 90 | 13 |
| Momentum | 70 | 67 |
| Stability | 89 | 27 |
| Investment | 67 | 25 |
| Short Interest | 53 | 43 |
| Valuation | ||
| P/E Ratio | — | — |
| P/B Ratio | — | 2.23 |
| P/S Ratio | — | — |
| EV/EBITDA | — | — |
| Dividend Yield | 5.9% | 0.0% |
| Profitability | ||
| ROE | 22.6% | -104.4% |
| ROA | 4.9% | — |
| Gross Margin | 71.2% | — |
| Operating Margin | 12.8% | — |
| Net Margin | 9.4% | — |
| Growth & Risk | ||
| Revenue Growth | 1.7% | — |
| Debt/Equity | 124.00 | 15.00 |
| Beta | 0.22 | 1.26 |
| Market | ||
| Market Cap | $72.13B | $295M |
Based on our 6-factor quantitative model, GSK currently has the higher composite score (74.3/100, Buy) and ranks #18 in our universe. However, the "better" stock depends on your investment goals, risk tolerance, and time horizon. We recommend reviewing the full factor breakdown above before making a decision.
Our comparison analyzes six quantitative factors: Quality (profitability and business strength, 30% weight), Momentum (price trends, 25%), Value (valuation attractiveness, 15%), Investment (capital allocation, 10%), Stability (financial health, 10%), and Short Interest (institutional positioning, 10%). Each factor is scored 0-100 and combined into a composite score.
GSK has the higher value score at 90/100 compared to NMRA at 13/100. A higher value score indicates the stock trades at a more attractive valuation relative to its earnings, book value, and cash flows.
Our stock rankings and comparisons are updated daily using the latest available market data, financial statements, and price information. Factor scores reflect the most recent quarterly filings and trailing price data.